OLP-1002 is Being Studied in the Treatment of Pain.

Inclusion Criteria

• Healthy male or females of any race, between 18 and 60 years of age, inclusive.
• Body mass index between 18.0 and 28.0 kg/m², inclusive.
• In good health, determined by no clinically significant findings from medical history, physical examination, single 12-lead electrocardiogram (resting heart rate > 45 bpm and 450 ms confirmed by repeat measurement.
• QRS duration > 110 ms confirmed by repeat measurement.
• PR interval > 220 ms confirmed by repeat measurement.
• findings which would make QT interval corrected for heart rate measurements difficult or QT interval corrected for heart rate data uninterpretable.
• history of additional risk factors for torsades de pointes (eg, heart failure, hypokalemia, family history of long QT syndrome).
• Female subjects who are pregnant or breastfeeding.
• History of alcoholism or drug/chemical abuse within 1 year prior to Screening.
• Alcohol consumption of > 21 units per week for males and >14 units per week for females. One unit of alcohol equals ½ pint (285 mL) of beer or lager, 1 glass (125 mL) of wine, or 1/6 gill (25 mL) of spirits.
• Positive alcohol breath test result or positive urine drug screen (confirmed by repeat) at Screening or Check-in.
• Positive hepatitis panel and/or positive human immunodeficiency virus test.
• Active skin conditions such as dermatitis, allergy, eczema, psoriasis, or abnormal healing.
• Tattoos, scars, or moles that in the opinion of the Investigator are likely to interfere with dosing or study assessments at any of the potential injection sites.
• Participation in a clinical study involving administration of an investigational drug (new chemical entity) in the past 90 days or 5 half-lives of the investigational product, whichever is longer, prior to Check-in.
• Use or intend to use any medications/products known to alter drug absorption, metabolism, or elimination processes, including St. John's wort, within 30 days prior to Check-in, unless deemed acceptable by the Investigator (or designee).
• Use or intend to use any prescription medications/products other than hormone replacement therapy, oral, implantable, transdermal, injectable, or intrauterine contraceptive concomitant medications within 14 days prior to Check-in, unless deemed acceptable by the Investigator (or designee).
• Use or intend to use slow-release medications/products considered to still be active within 14 days prior to Check-in, unless deemed acceptable by the Investigator (or designee).
• Use or intend to use any nonprescription medications/products including vitamins, minerals, and phytotherapeutic/herbal/plant-derived preparations within 7 days prior to Check-in, unless deemed acceptable by the Investigator (or designee) and/or Sponsor have given their prior consent.
• Use of tobacco- or nicotine-containing products within 3 months prior to Check-in.
• Receipt of blood products within 60 days prior to Check-in.
• Donation of blood from 3 months prior to Screening, plasma from 2 weeks prior to Screening, or platelets from 6 weeks prior to Screening.
• Poor peripheral venous access.
• Have previously completed or withdrawn from this study or any other study investigating OLP-1002, and have previously received the investigational product.
• Subjects who, in the opinion of the Investigator (or designee), should not participate in this study.
• Part A - PD assessment groups only
• Subjects considered non-acceptable responders to the intradermal capsaicin test at screening, defined as maximum VAS score of 9.0.